Header Logo

Connection

STEVEN I SHERMAN to Adult

Back to Details
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Adult.
STEVEN I SHERMAN
Connection Strength
0.483
Adult
  1. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599.
    View in: PubMed
    Score: 0.023
  2. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221.
    View in: PubMed
    Score: 0.022
  3. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467.
    View in: PubMed
    Score: 0.021
  4. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
    View in: PubMed
    Score: 0.020
  5. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105.
    View in: PubMed
    Score: 0.020
  6. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9.
    View in: PubMed
    Score: 0.020
  7. Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma. Endocr Pract. 2015 May; 21(5):461-7.
    View in: PubMed
    Score: 0.019
  8. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14.
    View in: PubMed
    Score: 0.019
  9. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61.
    View in: PubMed
    Score: 0.017
  10. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid. 2011 Dec; 21(12):1309-16.
    View in: PubMed
    Score: 0.015
  11. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8.
    View in: PubMed
    Score: 0.013
  12. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck. 2009 Sep; 31(9):1152-63.
    View in: PubMed
    Score: 0.013
  13. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 03; 359(1):31-42.
    View in: PubMed
    Score: 0.012
  14. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck. 2008 Jul; 30(7):883-8.
    View in: PubMed
    Score: 0.012
  15. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42.
    View in: PubMed
    Score: 0.011
  16. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003 Oct; 30(10):1371-7.
    View in: PubMed
    Score: 0.009
  17. Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid. 2002 Nov; 12(11):1009-16.
    View in: PubMed
    Score: 0.008
  18. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021 08; 31(8):1226-1234.
    View in: PubMed
    Score: 0.007
  19. The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence. Thyroid. 2020 10; 30(10):1490-1495.
    View in: PubMed
    Score: 0.007
  20. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986.
    View in: PubMed
    Score: 0.006
  21. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484.
    View in: PubMed
    Score: 0.006
  22. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid. 2019 04; 29(4):530-539.
    View in: PubMed
    Score: 0.006
  23. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck. 2019 06; 41(6):1928-1934.
    View in: PubMed
    Score: 0.006
  24. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018 10; 28(10):1301-1310.
    View in: PubMed
    Score: 0.006
  25. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372.
    View in: PubMed
    Score: 0.006
  26. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
    View in: PubMed
    Score: 0.006
  27. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
    View in: PubMed
    Score: 0.005
  28. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.005
  29. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4103-4109.
    View in: PubMed
    Score: 0.005
  30. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med. 1996 Aug; 101(2):192-8.
    View in: PubMed
    Score: 0.005
  31. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec; 106(12):1714-21.
    View in: PubMed
    Score: 0.005
  32. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90.
    View in: PubMed
    Score: 0.005
  33. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56.
    View in: PubMed
    Score: 0.005
  34. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12; 372(7):621-30.
    View in: PubMed
    Score: 0.005
  35. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7.
    View in: PubMed
    Score: 0.005
  36. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
    View in: PubMed
    Score: 0.005
  37. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994 Jun; 96(6):531-5.
    View in: PubMed
    Score: 0.005
  38. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26; 384(9940):319-28.
    View in: PubMed
    Score: 0.005
  39. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
    View in: PubMed
    Score: 0.004
  40. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
    View in: PubMed
    Score: 0.004
  41. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid. 2012 Apr; 22(4):347-55.
    View in: PubMed
    Score: 0.004
  42. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia Pac J Clin Oncol. 2011 Jun; 7 Suppl 2:34-40.
    View in: PubMed
    Score: 0.004
  43. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.004
  44. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother. 2011 Jul; 12(10):1491-7.
    View in: PubMed
    Score: 0.004
  45. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
    View in: PubMed
    Score: 0.004
  46. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2011 Feb; 137(2):157-62.
    View in: PubMed
    Score: 0.004
  47. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010 Nov; 95(11):5018-27.
    View in: PubMed
    Score: 0.004
  48. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck. 2010 Jul; 32(7):829-36.
    View in: PubMed
    Score: 0.003
  49. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95.
    View in: PubMed
    Score: 0.003
  50. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
    View in: PubMed
    Score: 0.003
  51. Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy. Anticancer Res. 2009 Nov; 29(11):4665-71.
    View in: PubMed
    Score: 0.003
  52. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10; 27(23):3794-801.
    View in: PubMed
    Score: 0.003
  53. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009 May; 49(5):1563-70.
    View in: PubMed
    Score: 0.003
  54. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1083-91.
    View in: PubMed
    Score: 0.003
  55. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med. 2007 Nov-Dec; 11(6):1408-15.
    View in: PubMed
    Score: 0.003
  56. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008 Jan; 39(1):15-20.
    View in: PubMed
    Score: 0.003
  57. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30.
    View in: PubMed
    Score: 0.003
  58. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54.
    View in: PubMed
    Score: 0.003
  59. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun; 91(6):2201-4.
    View in: PubMed
    Score: 0.003
  60. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32.
    View in: PubMed
    Score: 0.003
  61. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery. 2004 Dec; 136(6):1183-91.
    View in: PubMed
    Score: 0.002
  62. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
    View in: PubMed
    Score: 0.002
  63. Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr; 198(4):525-34; discussion 534-5.
    View in: PubMed
    Score: 0.002
  64. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003 Dec; 134(6):890-9; discussion 899-901.
    View in: PubMed
    Score: 0.002
  65. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003 Dec; 134(6):946-54; discussion 954-5.
    View in: PubMed
    Score: 0.002
  66. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003 Dec; 186(6):702-9; discussion 709-10.
    View in: PubMed
    Score: 0.002
  67. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003 Apr; 138(4):409-16; discussion 416.
    View in: PubMed
    Score: 0.002
  68. Prognostic factors in patients with H?rthle cell neoplasms of the thyroid. Cancer. 2003 Mar 01; 97(5):1186-94.
    View in: PubMed
    Score: 0.002
  69. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002 Jun; 137(6):641-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.